|
|
Volumn 15, Issue 5-6, 2010, Pages 230-234
|
|
Does R&D pay?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE;
ANASTROZOLE;
APRACLONIDINE;
ATORVASTATIN;
AZELASTINE;
CIDOFOVIR;
CIPROFLOXACIN;
DOCETAXEL;
DONEPEZIL;
EPROSARTAN;
FAMCICLOVIR;
FELBAMATE;
FENTANYL;
FLUTICASONE PROPIONATE;
FLUTICASONE PROPIONATE PLUS SALMETEROL;
GEMCITABINE;
IMIQUIMOD;
LAMIVUDINE;
LAMIVUDINE PLUS ZIDOVUDINE;
LOSARTAN;
MEROPENEM;
MIGLUSTAT;
NARATRIPTAN;
NATEGLINIDE;
PANTOPRAZOLE;
RANOLAZINE;
TAMSULOSIN;
TINIDAZOLE;
UNINDEXED DRUG;
ZAFIRLUKAST;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
INVESTMENT;
PATENT;
PROFIT;
REVIEW;
ANIMALS;
DRUG APPROVAL;
DRUG COSTS;
DRUG INDUSTRY;
HUMANS;
PATENTS AS TOPIC;
RESEARCH;
|
|
EID: 77649233779
PISSN: 13596446
EISSN: None
Source Type: Journal
DOI: 10.1016/j.drudis.2009.11.002 Document Type: Review |
|
Times cited : (9)
|
|
References (4)
|
